1. Establishment and characterization of novel preclinical models of aggressive lymphomas
1.A. Patient-validated lymphoma cell lines (PVLs):
Mantle cell lymphoma: 3 x (UPF1G, UPF1H, UPF7U)
Diffuse large B-cell lymphoma: 2 x (UPF4D, UPF8D)
Burkitt lymphoma: 1 x (UPF6T)
T-NHL: 2 x (UPF2CH, UPF3P)
1.B. Patient-derived xenograft (PDXs) mouse models
Mantle cell lymphoma: 8 x (VFN-M1-M8)
Diffuse large B-cell lymphoma: 6 x (VFN-D1-D5, VFN-R1)
Burkitt lymphoma: 1 x (VFN-B1)
T-NHL: 2 x (VFN-T1-T2)
2. Preclinical and translational research
2.A. Experimental treatment approaches
- proapoptotic treatment approaches targeting BCL2 and MCL1 antiapoptotic proteins
- polymere-drug conjugates for the treatment of cancer: HPMA-copolymer-bound doxorubicin and cytarbine, unmodified or conjugated with monoclonal antibodies for targeted drug delivery. Cooperation with dr. Tomas Etrych, Institute of Macromolecular Chemistry, Academy of Science of the Czech Republic
- role of angiogenesis in the biology of malignant lymphomas
- mechanisms of drug resistance
- clonal evolution associated with lymphoma relapse / progression. Coopereation with Childhood Leukemia Investigation Prague
- cyclin-dependent kinase inhibitors in experimental therapy of lymphomas. Cooperation with prof. Miroslav Strnad, University of Palacky at Olomouc